

Antonello Di Paolo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3670047/antonello-di-paolo-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136 papers	2,903 citations	32 h-index	47 g-index
143 ext. papers	3,300 ext. citations	5 avg, IF	4.73 L-index

#	Paper	IF	Citations
136	Predictive Biomarkers of drug response: Colorectal cancer as a model 2022 , 199-240		0
135	Myeloid neoplasms and autoimmune diseases: markers of association. <i>Clinical and Experimental Rheumatology</i> , 2022 , 40, 49-55	2.2	1
134	Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 865871	5.6	0
133	and Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. <i>Oncology Research</i> , 2021 , 28, 631-644	4.8	4
132	Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1025-1031	5.1	5
131	Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples. <i>Separations</i> , 2021 , 8, 63	3.1	0
130	Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib. <i>Frontiers in Oncology</i> , 2021 , 11, 672287	5.3	1
129	Pharmacokinetics of Non- β -Lactam β -Lactamase Inhibitors. <i>Antibiotics</i> , 2021 , 10,	4.9	1
128	Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
127	Myeloid neoplasms and autoimmune diseases: markers of association. <i>Clinical and Experimental Rheumatology</i> , 2021 ,	2.2	3
126	The CoV-2 outbreak: how hematologists could help to fight Covid-19. <i>Pharmacological Research</i> , 2020 , 157, 104866	10.2	25
125	A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 182, 113132	3.5	9
124	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2020 , 136, 16-17	2.2	0
123	Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020 , 10, 1428	5.3	22
122	Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. <i>Frontiers in Pharmacology</i> , 2020 , 11, 610806	5.6	6
121	Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, e331-e333	5.9	5
120	A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment. <i>Journal of Chemotherapy</i> , 2019 , 31, 105-108	2.3	5

119	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019 , 110, 32-41	7.5	12
118	The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019 , 9, 532	5.3	10
117	Precision Medicine in Lymphoma by Innovative Instrumental Platforms. <i>Frontiers in Oncology</i> , 2019 , 9, 1417	5.3	10
116	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 254-255	3.2	
115	Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. <i>Neurocritical Care</i> , 2019 , 31, 116-124	3.3	13
114	Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges. <i>Drugs</i> , 2018 , 78, 399-410	12.1	6
113	Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment. <i>Stem Cells Translational Medicine</i> , 2018 , 7, 305-314	6.9	41
112	Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells. <i>Stem Cells</i> , 2018 , 36, 633-640	5.8	21
111	Dermatological, Cardiovascular and Neurological Morphohistopathological Effects of Fluoropyrimidine-based Chemotherapy in Humans. <i>Clinical Cancer Drugs</i> , 2018 , 4,	0.2	1
110	A Common <i>mdr1</i> Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 602-609	3.2	6
109	The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018 , 8, 555	5.3	11
108	Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study. <i>Frontiers in Oncology</i> , 2018 , 8, 452	5.3	71
107	Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant <i>C. parapsilosis</i> candidemia. <i>Journal of Chemotherapy</i> , 2017 , 29, 376-379	2.3	5
106	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 767-773	3.5	11
105	Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	21
104	Simultaneous, But Not Consecutive, Combination With Folate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo. <i>Oncology Research</i> , 2017 , 25, 1129-1140	4.8	8
103	Pharmacogenetics and Personalized Medicine 2017 , 149-168		1
102	Personalized medicine in Europe: not yet personal enough?. <i>BMC Health Services Research</i> , 2017 , 17, 289	2.9	27

101	Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase. <i>Current Pharmaceutical Design</i> , 2017 , 23, 2028-2034	3.3	6
100	Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule. <i>Frontiers in Pharmacology</i> , 2017 , 8, 523	5.6	6
99	The and polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017 , 8, 88021-88033	3.3	10
98	The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016 , 109-130	0.3	
97	Oral administration of gentamicin for prophylaxis of KPC-producing <i>Klebsiella pneumoniae</i> gut colonization in patients treated with a novel parenchymal-sparing liver surgery: the GEN Gut study. <i>Intensive Care Medicine</i> , 2016 , 42, 124-5	14.5	2
96	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. <i>Blood</i> , 2016 , 128, 3951-3951	2.2	
95	First Case of <i>Trichoderma longibrachiatum</i> CIED (Cardiac Implantable Electronic Device)-Associated Endocarditis in a Non-immunocompromised Host: Biofilm Removal and Diagnostic Problems in the Light of the Current Literature. <i>Mycopathologia</i> , 2016 , 181, 297-303	2.9	13
94	Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 839-48	2.8	37
93	Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. <i>Epigenomics</i> , 2016 , 8, 1151-67	4.4	5
92	ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1419-1432	5.5	41
91	Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1253-67	5.5	2
90	Comment on "High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma". <i>Tumor Biology</i> , 2015 , 36, 7397-8	2.9	1
89	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. <i>Epigenomics</i> , 2015 , 7, 757-65	4.4	18
88	Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib. <i>Hematological Oncology</i> , 2015 , 33, 250-2	1.3	3
87	Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 22811-29	6.3	21
86	Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 4838-4838	2.2	
85	Different recommendations for daptomycin dosing over time in patients with severe infections. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1788-9	11.6	11
84	Oral gentamicin gut decontamination for prevention of KPC-producing <i>Klebsiella pneumoniae</i> infections: relevance of concomitant systemic antibiotic therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1972-6	5.9	51

83	The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. <i>Pharmacogenomics Journal</i> , 2014 , 14, 328-35	3.5	36
82	Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine 2014 , 2014, 904829		2
81	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014 , 9, 205-14	5	22
80	Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib. <i>Blood</i> , 2014 , 124, 3608-3608	2.2	1
79	Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , 2013 , 42, 250-5	14.3	36
78	Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 511-42	6.2	27
77	Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature. <i>Mycopathologia</i> , 2013 , 175, 129-34	2.9	15
76	The pharmacological bases of the antiangiogenic activity of paclitaxel. <i>Angiogenesis</i> , 2013 , 16, 481-92	10.6	116
75	Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 601-2	5.9	17
74	Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers. <i>Therapeutics and Clinical Risk Management</i> , 2013 , 9, 303-11	2.9	5
73	Pharmacokinetic drug-drug interaction and their implication in clinical management. <i>Journal of Research in Medical Sciences</i> , 2013 , 18, 601-10	1.6	141
72	Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 361-9	2.9	8
71	Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2012 , 41, e24-30	2.6	12
70	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , 2012 , 15, 275-86	10.6	53
69	Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter. <i>Clinical Cancer Research</i> , 2012 , 18, 4473; author reply 4474	12.9	
68	Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. <i>Current Topics in Medicinal Chemistry</i> , 2012 , 12, 1713-9	3	11
67	Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. <i>Neoplasia</i> , 2011 , 13, 217-29	6.4	26
66	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2011 , 43, 1015-21	3.3	8

65	Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. <i>Current Drug Metabolism</i> , 2011 , 12, 932-43	3.5	40
64	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011 , 104, 1262-9	8.7	77
63	Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics. <i>Scandinavian Journal of Infectious Diseases</i> , 2011 , 43, 721-7		17
62	Case report of a successful treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteremia and MRSA/vancomycin-resistant <i>Enterococcus faecium</i> cholecystitis by daptomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2458-9	5.9	19
61	Linezolid for endocarditis: a case series of 14 patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 679-82	5.1	15
60	Pharmacological issues of linezolid: an updated critical review. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 439-47.	4.2	68
59	A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 200-5	3.2	32
58	Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?. <i>EPMA Journal</i> , 2010 , 1, 495-502	8.8	18
57	Pharmacogenetics of Angiogenesis 2010 , 233-242		
56	Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections. <i>Journal of Chemotherapy</i> , 2009 , 21, 421-5	2.3	11
55	A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 965-9	3.5	11
54	Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 132-4	3.8	8
53	Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 34-42	3.8	41
52	ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. <i>Pharmacogenomics</i> , 2009 , 10, 1267-76	2.6	46
51	Vascular Endothelial Growth Factor-A (VEGF-A) Single Nucleotide Polymorphisms and Endometriosis: Still a Controversial Issue. <i>Journal of Endometriosis</i> , 2009 , 1, 94-101		2
50	Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. <i>British Journal of Cancer</i> , 2008 , 98, 1619-29	8.7	74
49	Serotonin syndrome and the T102-->C polymorphism of the 5-HT2A receptor: a case report. <i>Bipolar Disorders</i> , 2008 , 10, 655-6	3.8	5
48	Pharmacogenetics in oncology. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 74-78	1.6	0

47	A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2008 , 98, 1312-9	8.7	57
46	5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2749-55	12.9	47
45	Pharmacogenetics of Antiangiogenic Therapy 2008 , 477-486		
44	Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007. <i>Clinical Colorectal Cancer</i> , 2007 , 6, 407-22	3.8	16
43	Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. <i>Current Oncology Reports</i> , 2007 , 9, 109-14	6.3	64
42	Linezolid cerebrospinal fluid concentration in central nervous system infection. <i>Journal of Chemotherapy</i> , 2007 , 19, 90-3	2.3	15
41	Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 58, 585-93	3.5	10
40	In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma. <i>European Journal of Pharmacology</i> , 2006 , 549, 27-34	5.3	12
39	Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 809-16	1.9	27
38	A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 384-95	6.1	52
37	Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. <i>Current Clinical Pharmacology</i> , 2006 , 1, 311-23	2.5	18
36	Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens. <i>Clinical Colorectal Cancer</i> , 2005 , 4, 344	3.8	
35	Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 362-8	3.2	19
34	Genotype A1/A2 associated with neuroleptic malignant syndrome. <i>Bipolar Disorders</i> , 2005 , 7, 390-1	3.8	3
33	Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. <i>Journal of Chemotherapy</i> , 2005 , 17, 663-7	2.3	12
32	A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. <i>Clinical Cancer Research</i> , 2004 , 10, 1657-63	12.9	23
31	Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 505-6; author reply 507-8	6.1	6
30	Biologic basis of ovarian metastasis of colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2004 , 3, 223-4	3.8	0

29	Genetic determinants in the study of colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2004 , 4, 260-1	3.8	
28	Pharmacogenetics of neoplastic diseases: new trends. <i>Pharmacological Research</i> , 2004 , 49, 331-42	10.2	20
27	Drug therapeutic failures in emergency department patients. A university hospital experience. <i>Pharmacological Research</i> , 2004 , 49, 85-91	10.2	27
26	Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. <i>Pharmacological Research</i> , 2004 , 49, 493-9	10.2	33
25	An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. <i>Transplantation Proceedings</i> , 2004 , 36, 2787-90	1.1	21
24	Predicting survival with artificial neural networks. <i>Clinical Colorectal Cancer</i> , 2003 , 2, 245	3.8	1
23	Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. <i>Pharmacological Reviews</i> , 2003 , 55, 57-103	22.5	58
22	Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. <i>European Journal of Clinical Pharmacology</i> , 2002 , 58, 593-5	2.8	14
21	Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 508-18	3.8	38
20	Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 71, 263-71	6.1	5
19	Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 627-37	6.1	21
18	Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4006-14	2.2	130
17	Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 588-93	3.2	23
16	Chemoembolization is effective as second-line therapy in patients with colorectal carcinoma metastatic to the liver. <i>Clinical Colorectal Cancer</i> , 2002 , 2, 180-1	3.8	2
15	Irinotecan in 5-fluorouracil-refractory colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2002 , 2, 102-3	3.8	
14	Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. <i>Pharmacological Research</i> , 2002 , 46, 545-50	10.2	38
13	Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. <i>Annals of Oncology</i> , 2001 , 12, 1301-6	10.3	84
12	Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study. <i>Toxicology and Applied Pharmacology</i> , 2001 , 177, 149-56	4.6	7

11	Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. <i>British Journal of Cancer</i> , 2001 , 84, 1535-43	8.7	20
10	Pharmacogenetic determinants of anti-cancer drug activity and toxicity. <i>Trends in Pharmacological Sciences</i> , 2001 , 22, 420-6	13.2	52
9	Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naïve metastatic colorectal cancer patients. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3456-62	2.2	46
8	Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 375-82	3.2	10
7	Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 133-40	3.5	10
6	Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 205-12	3.5	46
5	An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 367-75	3.2	61
4	Chronic administration of suramin induces neurotoxicity in rats. <i>Journal of the Neurological Sciences</i> , 1997 , 152, 125-31	3.2	1
3	Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). <i>Clinical Cancer Research</i> , 1997 , 3, 265-72	12.9	66
2	Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 37, 409-14	3.5	32
1	Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines. <i>Pharmacological Research</i> , 1995 , 32, 135-9	10.2	9